中关村(000931.SZ)：下属公司北京华素盐酸纳曲酮片通过一致性评价

Core Viewpoint - Zhongguancun (000931.SZ) announced that its subsidiary Beijing Huasu Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the drug "Naltrexone Hydrochloride Tablets" (50mg), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - Beijing Huasu has successfully obtained the approval notice (Notification No. 2025B04969) for its Naltrexone Hydrochloride Tablets, indicating compliance with regulatory standards [1] - The drug is intended to block the pharmacological effects of exogenous opioid substances and serves as an auxiliary medication for preventing relapse in opioid-dependent individuals after detoxification [1]